However, theres a concerning rise in the use of unapproved, compounded GLP-1 drugs, which pose significant health risks
A separate KFF analysis from March about Medicare Part D spending data from the Centers for Medicare & Medicaid Services found that gross Medicare spending on the three newest versions of GLP-1 diabetes medicines (Ozempic, Rybelsus and Mounjaro) that also have been approved for weight loss skyrocketed from $57 million in 2018 to $5.7 billion in 2022
Known as the triple G obesity drug, retatrutide works differently from existing weight loss injections by targeting not just one, but three important hormone pathways in your body
Secondly, physicians prescribe them along with an individualized low-calorie, low-fat diet, and exercise program
These approaches work by stimulating the L-cells in your intestinal lining or by improving the sensitivity of GLP-1 receptors throughout your body
All claims are supported by published research data